<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053147_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133941</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHEH2012US019041</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20121211</transmissiondate>
		<reporttype>1</reporttype>
		<serious>2</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20120920</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20121205</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHEH2012US019041</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification>1</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>ND</patientinitial>
			<patientonsetage>48</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex>2</patientsex>
			<reaction>
				<primarysourcereaction>Patient had an ECG (electrocardiogram) and the physician did not like the results</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>ECG abnormal</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Electrocardiogram abnormal</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Headaches</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Headache</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Headache</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Heart palpitation</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Palpitations</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Palpitations</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120905</reactionstartdate>
				<reactionfirsttime>16</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Eyes look yellow</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Yellow ocular coloring</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Ocular icterus</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120913</testdate>
				<testname>Electrocardiogram</testname>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>TASIGNA</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>22-068</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>400</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>400 mg, BID</drugdosagetext>
				<drugdosageform>Capsule</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Chronic myeloid leukaemia</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20120821</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20120905</drugenddate>
				<drugtreatmentduration>16</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMN107</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Electrocardiogram abnormal</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Electrocardiogram abnormal</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Headache</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Headache</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Ocular icterus</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Ocular icterus</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Palpitations</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Palpitations</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>SERTRALINE</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>SERTRALINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>AMBIEN</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ZOLPIDEM TARTRATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>HYDROXYUREA</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>HYDROXYCARBAMIDE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHEH2012US019041 is an initial spontaneous report from a consumer (patient) via CVS Caremark specialty pharmacy received on 20 Sep 2012, with a follow-up report from consumer (patient) via CVS Caremark speciality pharmacy received on 05 Dec 2012. This report refers to a 48-year-old female patient. Concomitant medications included sertraline, Ambien (zolpidem tartrate) and Hydroxyurea (hydroxycarbamide). The patient received Tasigna (nilotinib) for the treatment of chronic myeloid leukemia without mention of remission from 21 Aug 2012 at a dose of 400 mg BID orally. On 05 Sep 2012, after starting Tasigna therapy, the patient experienced heart palpitations. Treatment with Tasigna was discontinued by the physician on the same day. On 13 Sep 2012, the patient had an ECG (electrocardiogram) and the physician did not like the results. The patient was going to see cardiologist on 21 Sep 2012. On an unspecified date, the patient stated that her eyes looked yellow and she experienced headaches. The outcome of the event palpitations was reported as condition unchanged. The outcome of the remaining events was not reported. The causality of the events was not reported. No further information was available.

Follow-up report from consumer (patient) via CVS Caremark speciality pharmacy received on 05 Dec 2012: Updated indication, therapy start date,concomitant drugs and events (eyes look yellow and headaches).</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
